Immutep Ltd., of Sydney, dosed the first patient in a new cohort of the phase I Two Active Immunotherapies in Melanoma (TACTI-mel) trial testing eftilagimod alpha (IMP321) with Keytruda (pembrolizumab, Merck & Co. Inc.). The additional cohort will enroll six patients who will be treated with 30 mg of eftilagimod, which is an antigen-presenting cell activator, starting at the first cycle of Keytruda for up to 12 months. Immutep plans to release data for some cohorts of the TACTI-mel trial in the middle of this year.